Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
暂无分享,去创建一个
C. Held | C. Cannon | E. Michelson | L. Wallentin | B. Scirica | P. Steg | C. Varenhorst | S. James | R. Storey | A. Himmelmann | S. Husted | K. Im | Jianping Guo | An H. Bui
[1] C. Held,et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes , 2014, Heart.
[2] R. Califf,et al. Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes , 2012, Circulation.
[3] P. Pais,et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. , 2011, Journal of the American College of Cardiology.
[4] J. Piccini,et al. Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk. , 2011, American heart journal.
[5] David A. Morrow,et al. Relationship Between Nonsustained Ventricular Tachycardia After Non–ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death: Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN , 2010, Circulation.
[6] A. Habets,et al. Defibrillator implantation early after myocardial infarction. , 2009, The New England journal of medicine.
[7] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[8] A. Skene,et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.
[9] Barry J Maron,et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardi , 2008, Journal of the American College of Cardiology.
[10] T. Young,et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Coun , 2008, Circulation.
[11] H. Huikuri,et al. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. , 2005, European heart journal.
[12] Eric Fain,et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.
[13] Pekka Raatikainen,et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. , 2003, Journal of the American College of Cardiology.
[14] R. Califf,et al. Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes , 2002, Circulation.
[15] K. Lee,et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. , 2000, The New England journal of medicine.
[16] Ric,et al. ELECTROPHYSIOLOGIC TESTING TO IDENTIFY PATIENTS WITH CORONARY ARTERY DISEASE WHO ARE AT RISK FOR SUDDEN DEATH , 2000 .
[17] S. Hohnloser,et al. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. , 1999, Journal of the American College of Cardiology.
[18] A. Kadish,et al. Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications. , 1998, Circulation.
[19] A. Camm,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.
[20] Bertram Pitt,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.
[21] L. Tavazzi,et al. Prevalence and Prognostic Significance of Ventricular Arrhythmias After Acute Myocardial Infarction in the Fibrinolytic Era GISSI‐2 Results , 1993, Circulation.
[22] M. Pfisterer,et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) , 1990, Journal of the American College of Cardiology.
[23] M. Weir,et al. The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .
[24] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.
[25] J. Fleiss,et al. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. , 1986, The American journal of cardiology.
[26] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.